The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

NCT02116712 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Lymphangioleiomyomatosis

Interventions

DRUG: Saracatinib

Sponsor

Tony Eissa

Collaborators

[object Object]
[object Object]